Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Immutep Limited
  6. News
  7. Summary
    IMM   AU000000IMM6


End-of-day quote. End-of-day quote Australian Stock Exchange - 11/26
0.49 AUD   -3.92%
11/25IMMUTEP : Results of Annual General Meeting
11/25IMMUTEP : AGM 2021 - Chairman's Address
11/25IMMUTEP : AGM 2021 - CEO's presentation
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Immutep : 2021 Annual General Meeting and Key Dates

10/12/2021 | 04:42am EST

ASX/Media Release

2021 Annual General Meeting and Key Dates

SYDNEY, AUSTRALIA - 12 October 2021 - Immutep Limited(ASX: IMM; NASDAQ: IMMP) advises that it intends to hold its 2021 Annual General Meeting, (AGM) on Friday, 26 November 2021 commencing at 10.00am (AEDT).

The Company further advises that the closing time and date for receipt of director nominations for candidates other than those recommended by the Board is 5:00 pm, Tuesday, 19 October 2021.

Virtual AGM

Due to the ongoing impact of the COVID-19 pandemic and in consideration of the safety of shareholders, employees and the broader community, the Company will hold the AGM virtually rather than at a physical location this year.

Shareholders will be provided with more information on how to participate in the AGM in the Notice of the Meeting which will be released later this month on the Company's ASX market announcements page.

Notice of Meeting

In accordance with s253RA of the Corporations Act 2001 (inserted by the Treasury Laws Amendment (2021 Measures No. 1) Act 2021)), the Company will send the Notice of Meeting to shareholders electronically.

Shareholders who normally receive a hard copy of AGM related documents are encouraged to provide their email address to the share registry, Boardroom Limited at enquiries@boardroomlimited.com.aubefore Thursday, 21 October 2021 to enable the Company to send the 2021 AGM related documentation by email.

Shareholders can also elect to receive future correspondence from the Company electronically by informing Boardroom Limited of this request via the above email address or by changing their communications election at https://www.investorserve.com.au/.

If you have not yet registered, you will need your shareholder information including SRN/HIN details.

This announcement was authorised for release by the Board of Immutep Limited.

About Immutep

Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer, infectious disease and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Immutep's current lead product candidate is eftilagimod alpha ("efti" or "IMP321"), a soluble LAG-3 protein, which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease.

Immutep Limited, Level 12, 95 Pitt Street, Sydney NSW 2000

ABN: 90 009 237 889

Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep's large pharmaceutical partners.

Further information can be found on the Company's website www.immutep.comor by contacting:

Australian Investors/Media:

Catherine Strong, Citadel-MAGNUS

+61 (0)406 759 268; cstrong@citadelmagnus.com

U.S. Media:

Tim McCarthy, LifeSci Advisors

+1 (212) 915.2564; tim@lifesciadvisors.com

Immutep Limited, Level 12, 95 Pitt Street, Sydney NSW 2000

ABN: 90 009 237 889


Immutep Ltd. published this content on 12 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 October 2021 08:41:01 UTC.

ę Publicnow 2021
All news about IMMUTEP LIMITED
11/25IMMUTEP : Results of Annual General Meeting
11/25IMMUTEP : AGM 2021 - Chairman's Address
11/25IMMUTEP : AGM 2021 - CEO's presentation
11/22IMMUTEP : Successfully Completes Recruitment for Phase II TACTI-002 Study of LAG-3 Therapy..
11/22IMMUTEP : Goetzpartners securities -Data highlights efti efficacy and potential central ro..
11/19Immutep Completes Recruitment for Phase 2 Study of Therapy Candidate for Several Types ..
11/18Immutep Completes Recruitment for Phase 2 Cancer Trial
11/18IMMUTEP : Phase II TACTI-002-002 trial recruitment successfully completed
11/18Immutep Limited Announces the Enrollment of Last Patient in the Expansion Stage of Part..
11/17IMMUTEP : Maxim Group - AIPAC Presentation at SITC Builds on Prior Data, Prepping to Go Pi..
More news
Analyst Recommendations on IMMUTEP LIMITED
More recommendations
Sales 2022 1,33 M 0,94 M 0,94 M
Net income 2022 -38,2 M -27,2 M -27,2 M
Net cash 2022 58,2 M 41,4 M 41,4 M
P/E ratio 2022 -7,59x
Yield 2022 -
Capitalization 417 M 297 M 297 M
EV / Sales 2022 271x
EV / Sales 2023 7,73x
Nbr of Employees -
Free-Float 85,2%
Duration : Period :
Immutep Limited Technical Analysis Chart | IMM | AU000000IMM6 | MarketScreener
Technical analysis trends IMMUTEP LIMITED
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 4
Last Close Price 0,49 AUD
Average target price 1,15 AUD
Spread / Average Target 134%
EPS Revisions
Managers and Directors
Marc Voigt Chief Executive Officer, CFO & Executive Director
David Fang Finance Director & Assistant Secretary
Russell John Howard Non-Executive Chairman
FrÚdÚric Triebel Chief Scientific & Medical Officer
Deanne Miller COO, Secretary & General Counsel
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431